Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

被引：3
作者：
Wu, Yuanlin [1 ]
Yu, Guangmao [1 ]
Jin, Ketao [2 ]
Qian, Jun [3 ]
机构：
[1] Shaoxing Peoples Hosp, Dept Thorac Surg, Shaoxing, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Colorectal & Anal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Xinchang Peoples Hosp, Affiliated Xinchang Hosp, Dept Colorectal Surg, Xinchang, Zhejiang, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
non-small cell lung cancer; immunotherapy; combination therapy; cancer vaccines; tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-CHECKPOINT INHIBITOR; TYROSINE KINASE INHIBITORS; REGULATORY T-CELLS; PD-L1; EXPRESSION; ADVANCED NSCLC; OPEN-LABEL; PHASE-III; 1ST-LINE NIVOLUMAB; TARGETED THERAPIES;
D O I：
10.3389/fimmu.2024.1349502
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.
引用
收藏
页数：31
相关论文
共 208 条
[1]   Risk factors of Lung Cancer in nonsmoker [J].
Akhtar, Nahid ;
Bansal, Jeena Gupta .
CURRENT PROBLEMS IN CANCER, 2017, 41 (05) :328-339
[2]   Cancer immunotherapies, their safety and toxicity [J].
Alatrash, Gheath ;
Jakher, Haroon ;
Stafford, Patricia D. ;
Mittendorf, Elizabeth A. .
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) :631-645
[3]   Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature [J].
Albaba, Hamzeh ;
Lim, Charles ;
Leighl, Natasha B. .
PHARMACOECONOMICS, 2017, 35 (12) :1195-1209
[4]   Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment [J].
Alduais, Yaser ;
Zhang, Haijun ;
Fan, Fan ;
Chen, Jing ;
Chen, Baoan .
MEDICINE, 2023, 102 (08) :E32899
[5]   PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].
Alsaab, Hashem O. ;
Sau, Samaresh ;
Alzhrani, Rami ;
Tatiparti, Katyayani ;
Bhise, Ketki ;
Kashaw, Sushil K. ;
Iyer, Arun K. .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[6]   Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Kurata, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
Carpeno, J. de Castro ;
Faivre-Finn, C. ;
Reck, M. ;
Vansteenkiste, J. ;
Spigel, D. R. ;
Wadsworth, C. ;
Melillo, G. ;
Taboada, M. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350
[7]   Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].
Antonia, Scott ;
Goldberg, Sarah B. ;
Balmanoukian, Ani ;
Chaft, Jamie E. ;
Sanborn, Rachel E. ;
Gupta, Ashok ;
Narwal, Rajesh ;
Steele, Keith ;
Gu, Yu ;
Karakunnel, Joyson J. ;
Rizvi, Naiyer A. .
LANCET ONCOLOGY, 2016, 17 (03) :299-308
[8]  
Anupozu R., 2020, Medicine International Journal of Advances in Scientific Research, DOI [10.21817/ijpsr/2020/v11i9/201109001, DOI 10.21817/IJPSR/2020/V11I9/201109001]
[9]   Towards precision medicine [J].
Ashley, Euan A. .
NATURE REVIEWS GENETICS, 2016, 17 (09) :507-522
[10]   PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs [J].
Bai, Yuchen ;
Chen, Xiaoxia ;
Hou, Likun ;
Qian, Jun ;
Jiang, Tao ;
Zhou, Caicun ;
Ciebiada, Maciej .
CANCER BIOLOGY & MEDICINE, 2018, 15 (04) :434-+
12345678910